{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-003761","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-08-03T13:28:21+00:00","discovered_at":"2026-08-03T13:29:00.311626+00:00","generated_at":"2026-08-03T13:29:05.497878+00:00","sec_items":["8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Silexion Therapeutics appoints Avner Lushi to audit committee after Peled resignation","bullets":["Professor Amnon Peled resigned from board and audit committee effective Aug 1, 2026 for personal reasons, no disagreement.","Avner Lushi, existing independent board member, appointed to audit committee effective Aug 1, 2026.","Audit committee now has three independent members: Dror J. Abramov (Chair), Ruth Alon, and Avner Lushi, restoring Nasdaq compliance.","Lushi is Managing Partner and CEO of Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF)."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-003761","json":"https://secwatch.observer/filing/0001178913-26-003761.json","markdown":"https://secwatch.observer/filing/0001178913-26-003761.md","text":"https://secwatch.observer/filing/0001178913-26-003761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003761/0001178913-26-003761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003761/zk2635816.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T13:29:05.497878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}